Macroautophagy (hereafter referred to as autophagy) can increase or decrease the amount of cell death in response to various stimuli. To test whether autophagy also controls the characteristics associated with dying cells, we studied tumor cell killing by epidermal growth factor receptor-targeted diphtheria toxin (DT-EGF). DT-EGF kills epithelial and glioblastoma tumor cells with similar efficiency but by different mechanisms that depend on whether the cells activate autophagy when treated with the drug. Dying cells in which autophagy is induced selectively release the immune modulator high-mobility group B1 (HMGB1) without causing lysis of the cell membrane and classical necrosis. Conversely, cells that are killed by DT-EGF where autophagy is blocked, activate caspases but retain HMGB1. These data suggest that it may be feasible to manipulate the immunogenicity of dying cells by increasing or decreasing autophagy.
Autophagy
1 regulates the amount of cell death that occurs in response to specific stimuli 2, 3 for example, by blocking apoptosis after growth factor depletion 4, 5 or exposure of cells to various other apoptotic stimuli, 6 protecting against caspase-independent death 7 or preventing necrosis in apoptosisincompetent cells that are subjected to severe metabolic stress. 8 Although it is still unclear under which conditions autophagy leads to cell death, 9 autophagic cell death 3 has been reported in response to external insults including DNA damaging agents, 10 caspase inhibitors 11 (although a more recent study raised questions about this conclusion 12 ) , and a large variety of anticancer drugs. 13 Autophagy can also contribute to cell death during normal development.
14 Thus autophagy can both positively and negatively regulate the amount of cell death that occurs in response to a stimulus.
The biological response to cell death stimuli such as treatment with anticancer drugs is determined both by the absolute amount of cell death and the characteristics of the dying cells. For example, apoptosis is usually non-inflammatory while necrosis usually causes an immune response. This difference is determined by the release of immunogenic stimulators especially the DNA-binding protein high-mobility group B1 (HMGB1), which is usually (but not always 15 ) retained in apoptotic nuclei but released during necrosis. 16 Although it is well established that autophagy can regulate the amount of cell death in response to a death stimulus, it is less clear how autophagy regulates characteristics of dying cells such as the release of HMGB1. To address this question, we asked how autophagy affects cells that are destined to die in different ways by treating tumor cells with a targeted toxin, 17 epidermal growth factor receptor (EGFR)-targeted diphtheria toxin (DT-EGF), which blocks protein synthesis and kills tumor cells in an EGFR-dependent manner as demonstrated by loss of metabolic activity, 18 clonogenicity, and the regression of established tumors. 19 
Results
We evaluated the cytotoxicity of DT-EGF 18 on EGFR-positive glioblastoma (U87MG and U373MG) and epithelial (HeLa and HN12) cancer cells using clonogenic survival (Figure 1a ) assays by treating with increasing doses of the targeted toxin for 24 h, then washing away the drug and allowing surviving cells to recover and undergo clonogenic growth for up to 2 weeks. In all cases, we obtained similar dose-dependent cell death as demonstrated by loss of clonogenic capacity. Previous studies 19 demonstrated that in addition to loss of metabolic activity as measured in cell viability assays, treatment with DT-EGF causes the regression of established glioblastoma tumors indicating that the drug causes bona fide glioblastoma cell death rather than growth arrest. Like many other anticancer agents, targeted toxins usually kill tumor cells by activating caspase-dependent apoptosis (reviewed in Thorburn 20 ). However, time-lapse microscopy ( Figure 1b ) showed that the morphology of the dying cells was markedly different with only the epithelial cells displaying typical characteristics of caspase-dependent apoptosis such as membrane blebbing and cellular fragmentation, whereas dying glioma cells rounded up but showed no signs of apoptosis or membrane rupture. Western blotting of the caspase substrate poly ADP-ribose polymerase (PARP) (Figure 1c ) and measurements of the activity of effector caspases (Supplementary Figure 1A) showed that DT-EGF activated caspases in the epithelial cells but not in the glioblastoma cells. However both U87MG and HeLa cells displayed robust caspase activation after treatment with lexatumumab, an antibody that activates the Tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor DR5 (Supplementary Figure 1B) indicating that both cell types contain functional caspases and could undergo apoptosis. Furthermore caspase inhibition protected against DT-EGF in HeLa cells but not in U87MG cells (Supplementary Figure 1C) .
We analyzed the proteome of dying U87MG cells treated with lexatumumab or DT-EGF. 2D-DIGE allows simultaneous analysis of different protein samples by labeling each sample with a different CyDye then combining the samples and separating them on the same gel. Lexatumumab caused numerous changes to the whole cell proteome, shown by many red and green spots that indicate differences between the samples (Figure 2a ). Extensive changes in the proteome are expected in apoptotic cells where caspases cleave hundreds of substrates. 21 In contrast, U87MG cells dying as a result of DT-EGF treatment displayed very few changes to the whole cell proteome as shown by the lack of green and red spots and the abundance of yellow spots (Figure 2a) . When the 2D gels were quantitated using a two-fold threshold as the cutoff for counting differences, 241 out of 2464 (9.8%) spots were different between the control and lexatumumab-treated samples, whereas only 2.4% of proteins were different between the control and DT-EGF-treated cells. These data indicate that the U87MG cells treated with DT-EGF are not undergoing apoptosis or apoptosis-like death caused by other proteases that cleave many substrates. Moreover, there was no apparent loss of soluble proteins as would be expected if there was abrupt lysis of the cell membrane as in typical necrosis.
One notable proteomic change induced by DT-EGF involved an apparent pI shift in a protein (Figure 2a boxed region) that was identified by mass spectrometry as isoforms of the translation eukaryotic elongation factor eEF2alpha (eEF2). This protein is the direct catalytic target of diphtheria toxin, which ADP ribosylates eEF2 on a unique dipthamide residue. However, the pI shift and western analysis (not shown) indicated that the modification caused by DT-EGF also involved phosphorylation. Because eEF2 kinase regulates autophagy in glioblastoma cells, 22 we asked if DT-EGF induces autophagy in U87MG cells. Upon induction of autophagy, the microtubule-associated light chain 3 (LC3) is conjugated to phosphatidylethanolamine and incorporated into autophagosomes. 1 This can be visualized by looking for the formation of foci of a green fluorescent protein (GFP) tagged version of LC3 (GFP-LC3). 23 DT-EGF induced GFP-LC3 foci in glioblastoma cells (Figure 2b and c) similar to that seen with the strong autophagy inducer trehalose. 24 when lysosomal protease inhibitors were used together with DT-EGF 25 and processing of the autophagy cargo substrate betaine homocysteine methyltransferase (BHMT) using a GST-tagged BHMT construct 26 ( Figure 3b ). As has been noted in other systems, detection of LC3-I was variable. At later times, after DT-EGF or trehalose treatment, we detected increased numbers of mCherry but not GFP labeled structures from a tandem labeled GFP-mCherry-LC3 expression construct. This protein displays green and red fluorescence in autophagosomes but only shows red fluorescence after the autophagosomes fuse with lysosomes 27, 28 indicating that DT-EGF causes the maturation of autophagosomes and fusion with lysosomes (Supplementary Figure 3) . DT-EGF also induced autophagy in U373MG cells as shown in Figure 3b using the GST-BHMT assay. DT-EGF treatment of the epithelial cell lines that we tested did not increase autophagy as indicated by LC3-II formation (Figure 3a Figure 5) . These data indicate that DT-EGF induces autophagosome formation and autophagic flux in some but not all tumor cells, suggesting that the different characteristics of the dying cells could be related to the drug's ability to activate autophagy in the different cell types.
To test if autophagy controls the amount of DT-EGFinduced death, we performed siRNA knockdown of autophagy regulators, treated with increasing doses of DT-EGF for 24 h, then removed the drug and cultured cells for 2 weeks to allow colony growth of surviving cells. Alternatively, autophagy was increased by pre-treatment with trehalose, and cell death after treatment with DT-EGF was monitored by time-lapse microscopy or clonogenic survival. Inhibition of autophagy increased the efficiency of DT-EGF killing in the clonogenic growth assay (Figure 4a ). Conversely, increasing autophagy with trehalose delayed (Figure 4b ) and slightly inhibited (Figure 4c ) DT-EGF-induced glioblastoma cell death. In the U87MG cells, inhibition of autophagy by siRNA knockdown of Atg5 allowed induction of caspase 3/7 activity in response to DT-EGF (Figure 4d ). These data indicate that the glioblastoma cells do not undergo autophagic cell death but rather are protected by the DT-EGF-induced autophagy and suggest that this occurs because autophagy prevents more efficient caspase-dependent death. Increasing autophagy prior to DT-EGF treatment also protected HN12 epithelial cells as shown by clonogenic assay (Supplementary Figure 6A) and time-lapse microscopy (Supplementary Figure 6B) . The protection conferred by trehalose was greater in the epithelial cells than the glioblastoma cells consistent with the idea that in glioblastoma cells, trehalose-induced autophagy was merely added to that produced by DT-EGF on its own.
We next asked whether the cells that activate autophagy after DT-EGF treatment released HMGB1. DT-EGF-treated U87MG cells released HMGB1 into the extracellular media as shown by time-lapse microscopy of GFP-HMGB1-transfected cells (Figure 5a ) and western blotting (Figure 5b) . Moreover, this release was controlled by autophagy as shown by knockdown of Atg5, Atg7, or Atg12, which prevented HMGB1 release in DT-EGF-treated U87MG cells as detected by western blotting or time-lapse microscopy of GFP-HMGB1 (Figure 5a and b, Supplementary Figure 8A ). These data indicate that the formation of autophagosomes is required for the release of HMGB1. Release occurred after the GFP-HMGB1 protein became localized in a punctate pattern as shown in the magnified image in Figure 5a . These HMGB1-positive structures, co-localized with a few of the LC3-positive dots (see arrows in Supplementary Figure 7) consistent with the idea that a subset of autophagosomal structures contains HMGB1 prior to its release from the cell.
HMGB1 release usually occurs in cells that are undergoing classical necrotic cell death marked by abrupt membrane lysis and the release of soluble proteins. 16 However, unlike the necrotic, H 2 O 2 -treated U87MG cells, which also released lactate dehydrogenase (LDH) (Figure 6c ) and were stained with propidium iodide (Figure 6a and b) indicating that their cytoplasmic membranes were lysed, the DT-EGFtreated cells did not display other necrotic characteristics. Indeed there was greater propidium iodide staining in Together with the limited changes in the whole cell proteome in the dying DT-EGF-treated U87MG cells (Figure 2a) , these data indicate that the HMGB1 release from these dying cells is not associated with membrane lysis and necrosis but instead represents selective release of the HMGB1 protein from the cell. Conversely, DT-EGF-treated epithelial cells (which activate caspases and undergo apoptosis) did not release significant amounts of HMGB1 (Figure 6d and Supplementary  Figure 8) . However, when we stimulated autophagy with trehalose, then treated HN12 epithelial cells with DT-EGF, this caused HMGB1 release from the dying cells (Figure 6d ) without significant release of LDH (Figure 6e ). This release is due to the autophagy itself, because similar levels of HMGB1 release occur with treatment by trehalose alone (Figure 6d ).
Discussion
Manipulation of autophagy and necrosis may be useful in cancer therapy. 29, 30 For example, it may be possible to increase the efficiency of tumor cell killing in response to chemotherapeutic drugs by simultaneously inhibiting autophagy. 31 Our data support these ideas but add a new level of complexity by showing that in addition to regulating the amount of cell death, autophagy can control the characteristics of the dying cells by regulating the selective release of HMGB1, and thus selectively controlling an important characteristic of dying cells that is usually associated with necrosis. DT-EGF induces autophagy more effectively in the glioblastoma cell lines that we tested compared with the epithelial tumor cell lines tested; however, further studies will be needed to determine whether this is a generally consistent difference among cell types, and, if it is to uncover the basis for the difference. Our data show that even in cells such as U87MG cells, which die through a mechanism that displays characteristics of neither apoptosis or necrosis, the autophagy that occurs in the dying cells protects the tumor cells from the drug (i.e. causes a leftward shift in the dose response curve); that is, although the drug induces autophagy and then the cells die, this is not a case of autophagic cell death. In fact, the autophagy that is induced by DT-EGF in U87MG cells inhibits caspase activation and thus explains why they don't activate apoptosis. Tumor cells that are dying with increased autophagy (either caused by DT-EGF alone in the case of the glioblastoma cells or when autophagy is further increased with trehalose in epithelial tumor cells) selectively release the nuclear HMGB1 protein, but do so without displaying other characteristics of necrosis such as LDH release or loss of membrane integrity such that propoidium iodide can stain DNA. Although HMGB1 release is usually considered to be a marker of necrosis, activated monocytes and macrophages can secrete HMGB1 without undergoing necrosis 32 and some apoptotic stimuli can result in the release of HMGB1 under some conditions. 15, 33 We speculate that these instances of HMGB1 release may occur when the apoptotic cells also have high levels of autophagy.
HMGB1 enhances the immune response to poorly immunogenic apoptotic cells, 34 and when dying tumor cells release HMGB1, they activate a toll-like receptor-4-dependent, tumorspecific immune response. 33 This has led to the idea that by manipulating the death mechanisms to promote immunogenic tumor cell killing, it may be feasible to increase the long-term effectiveness of anticancer treatment by inducing an immune response that subsequently seeks out and destroys tumor cells that have avoided being killed by the drug. [35] [36] [37] To achieve such a response it is necessary that tumor cells die (so that tumor antigens can be generated and recognized) and that the immune system is stimulated by the HMGB1. Our data suggest a way to achieve this manipulation by increasing autophagy in cells that are destined to die, and thus cause the dying cells to release HMGB1. In situations where the drug not only kills the cells but also induces autophagy (as with DT-EGF treatment of the U87MG cells), the same agent may achieve both objectives. Alternatively, one could imagine adopting a strategy where one might inhibit autophagy to switch the tumor cell death mechanism towards caspasedependent apoptosis without release of HMGB1. Further studies will be necessary to determine which scenario may be more effective to maximize antitumor treatment in the long term and whether the ability of autophagy to reduce the amount of tumor cell killing is a benefit or a handicap compared with the ability of autophagy to cause HMGB1 release, and potentially increase the immunogenicity of the dying cells.
There are numerous mechanistic connections between apoptosis, necrosis, and autophagy 38, 39 suggesting that different death mechanisms are intimately related. We suggest that a spectrum of characteristics can be displayed by a dying cell and that this is regulated in part by the amount of autophagy that occurs as they die. When autophagy is not activated, it is easier to activate caspases and dying cells undergo apoptosis; conversely, when autophagy is high, caspase activation is blocked but cells that are destined to die can release HMGB1 without membrane lysis and true necrosis. Thus, we propose that autophagy can regulate the amount of death in response to a particular stimulus and the characteristics associated with the dying cells and that the overall biological effect of autophagy manipulation during treatment with targeted anticancer drugs such as DT-EGF that kill tumor cells may depend on both aspects.
Materials and Methods
Cells and reagents. HN12 cells were provided by Andrew Yeudall and other cells were obtained from ATCC. Lexatumumab was provided by Human Genome Sciences and used as described earlier. 40 Trehalose, a potent autophagy inducer, 24 was obtained from Sigma (St Louis, MO) and used at 100 mM. zVAD.fmk was used at 50 mM.
Cell death and autophagy assays. For clonogenic growth assays, cells in triplicate treated with three-fold dilutions up to 10 ng/ml DT-EGF for 24 h, drug was removed, cells were washed and maintained in growth media for 10-14 days, fixed and stained with 0.4% crystal violet. As the glioma cells do not form tight colonies, stained cells were solubilized in 33% acetic acid and absorbance was read at 540 nm. Values were normalized to non-treated sample. Clonogenic assays and HMGB1 release experiments with siRNA knockdown were performed 3 days after siRNA knockdown, using siRNAs and transfection reagents from Dharmacon (Lafayette, CO). For time-lapse microscopy and other experiments with a single dose of DT-EGF, the toxin was used at 50 or 100 ng/ml. Caspase assays were performed using Promega Caspase-Glo 3/7 reagent. LDH release was measured using LDH Cytotoxicity Detection Kit from Takara Bio Inc. (Seta 3-4-1, Otsu, Shiga, Japan). Time-lapse microscopy was performed on a Zeiss Axiovert 200 microscope equipped with an environmental chamber to maintain cells at 371C and 5% CO 2 .
Images were captured with a Hamamatsu Orca CCD camera every 15-30 min using the Improvision Volocity program. Formation of autophagic vesicles was monitored by GFP-LC3 aggregation in stably expressing polyclonal cell lines, for quantitation the percentage of cells with 410 GFP-LC3 dots were scored as positive after counting B100 randomly chosen cells from two separate experiments. Autophagic flux assays were performed by western blotting for LC3-II formation, after treatment with DT-EGF in the presence or absence of lysosomal protease inhibitors as recommended by Mizushima and Yoshimori, 25 by monitoring the processing of a GST-tagged version of the autophagy cargo protein betaine homocysteine methyltransferase as described by Mercer et al. 26 and by stably expressing a tandem GFP, mCherry-labeled LC3 protein that retains both green and red fluorescence in autophagosomes, but retains only red fluorescence after fusion with lysosomes as described by Kimura et al. 2D-DIGE. Supplies and protocols were from Amersham Biosciences/GE Healthcare (Piscataway, NJ). Fifty micrograms of protein were minimally labeled with Cy3 or Cy5 dye on ice for 30 min, combined and brought to a final volume of 450 ml in 7 M urea, 2 M thiourea, 4% CHAPS, 40 mM DTT, 0.002% bromophenol blue, and 0.5% pharmalytes; rehydrated overnight onto a 24 cm immobilized pH gradient strip (IPG 3-10 NL) and isoelectric focused at 500 V for 100 Vhr, 1000 V for 1000 Vhr, and 8000 V for 62 500 Vhr on a IPGphor apparatus. IPG strips were equilibrated for 15 min in a DTT solution, followed by reaction with iodoacetamide solution and applied to a precast 8-16% SDS-PAGE gel (Jule Inc., Milford, CT) for electrophoresis at a constant 20 W/gel at 251C in an Ettan DALT 12 electrophoresis unit. Labeled proteins were visualized by scanning the gels on a Typhoon 9400 scanner. DeCyder software (v. 5.0) was used for spot detection and relative quantification of proteins based on the fluorescence images. Peak volumes and ratios were measured for each protein spot in the two fluorescent channels (Cy3 and Cy5). Proteins to be excised and identified were selected using the DeCyder Differential In-gel Analysis Module. Individual DIGE gels were matched using the Biological Variation Analysis (BVA) Module. Protein spot excision and in-gel enzymatic digestion were performed automatically. Digests were analyzed by MALDI-TOF MS (Voyager DE-PRO, Applied Biosystems, Foster City, CA) and spectra were collected over the range m/z 500-5000. Spectra were processed using ProTS Data (Efeckta Technologies, Steamboat Springs, CO) to generate centroided peak lists that were submitted to Mascot (v 2.1, Matrix Science, Boston, MA) and Protein Prospector (v 4.21.1, UCSF, CA) for database searching.
